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Abstract
Background: Although a number of studies have shown good results in treating children with
antiretroviral drugs (ARVs) in hospital settings, there is limited published information on results in
pediatric programs that are nurse-centered and based in health centers, in particular on the
psychosocial aspects of care.
Methods: Program treatment and outcome data were reported from two government-run health
centers that were supported by Médecins Sans Frontières (MSF) in Kigali, Rwanda between
October 2003 and June 2007. Interviews were held with health center staff and MSF program
records were reviewed to describe the organization of the program. Important aspects included
adequate training and supervision of nurses to manage ARV treatment. The program also
emphasized family-centered care addressing the psychosocial needs of both caregivers and children
to encourage early diagnosis, good adherence and follow-up.
Results: A total of 315 children (< 15 years) were started on ARVs, at a median age of 7.2 years
(range: 0.7–14.9). Sixty percent were in WHO clinical stage I/II, with a median CD4% of 14%.
Eighty-nine percent (n = 281) started a stavudine-containing regimen, mainly using the adult fixed-
dose combination. The median follow-up time after ARV initiation was 2 years (interquartile range
1.2–2.6). Eighty-four percent (n = 265) of children were still on treatment in the program. Thirty
(9.5%) were transferred out, eight (2.6%) died and 12 (3.8%) were lost to follow-up. An important
feature of the study was that viral loads were done at a median time period of 18 months after
starting ARVs and were available for 87% of the children. Of the 174 samples, VL was < 400 copies/
ml in 82.8% (n = 144). Two children were started on second-line ARVs. Treatment was changed
due to toxicity for 26 children (8.3%), mainly related to nevirapine.
Conclusion: This report suggests that providing ARVs to children in a health center/nurse-based
program is both feasible and very effective. Adequate numbers and training of nursing staff and an
emphasis on the psychosocial needs of caregivers and children have been key elements for the
successful scaling-up of ARVs at this level of the health system.
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Treatment of children with the acquired immunodefi-
ciency syndrome (AIDS) using antiretroviral drugs (ARVs)
has been a major challenge in the fight against the human
immunodeficiency virus (HIV), especially in resource-
constrained settings. In many African countries, the short-
age of human resources for health is one of the major bar-
riers to achieve universal access to HIV treatment and care.
In particular, reliance on doctor and hospital-centered
care hampers the ability to scale-up antiretroviral treat-
ment (ART), and task shifting, the process of delegation of
tasks to health workers with lower qualifications, has
become a recognized strategy [1-4].
While there have been a number of studies showing good
outcomes in treating pediatric populations with ARVs in
resource-constrained settings [5-16], these programs have
essentially been carried out in hospital settings and/or
with significant physician involvement. Although nurse-
based ART provision in health centers could increase the
coverage of ART, it is not clear whether this compromises
quality in terms of outcomes. There are no published
studies demonstrating detailed methods and treatment
outcomes of children in health centers staffed by nurses.
In particular, there is limited published information on
how to address the psychosocial issues related to HIV, a
major challenge for pediatric ART programs [17], in set-
tings with few specialized personnel available.
As in most African countries, Rwanda has an acute short-
age of physicians and is relatively better resourced with
nurses [18]. In a recent simulation model, it was esti-
mated that, relying on a physician-centered service provi-
sion model, 51% of the total physician capacity of the
government of Rwanda would be absorbed by HIV care
and treatment by the end of 2008 [19]. Thus, it is com-
pletely logical to make greater use of nurses to manage
HIV care, but the question remains whether doing so leads
to good quality outcomes, especially for pediatric
patients.
This report describes the nurse-centered pediatric ARV
program implemented in two government health centers
in Kigali, Rwanda, with details of its psychosocial aspects
and treatment outcomes.
Methods
Design
Retrospective analysis of routinely collected outcomes
from the ARV program in two health centers in Kigali,
combined with interviews with key health center and
Médecins Sans Frontières (MSF) staff. MSF reports since
program inception were also reviewed.
Setting
Rwanda, with a population of around 9 million inhabit-
ants, has an overall HIV prevalence of 3% and more than
7% in urban areas [20]. The national ART program,
launched in 2003, was first established mostly in the dis-
trict hospitals, with subsequent decentralization to the
health centers. From 2004 on, a gradual scaling-up was
seen. The latest estimate in 2006 by TRAC (Treatment and
Research AIDS Center) of the number of HIV-infected
children was 13,901 with half of them (6951) in need of
ARVs [21]. By the end of May 2007, almost half (3255)
had benefited from ART.
Health worker distribution in Rwanda and their roles 
within the HIV care program
With one physician/50,000 habitants and one nurse/3900
habitants, Rwanda is clearly short of physicians but is rel-
atively better resourced with nurses [22]. In addition, 80–
90% of the population is living in rural areas and mainly
relies on care from primary health centers, staffed by
nurses. Up to now, HIV/ART care delivery has essentially
been provided by physicians, with nurses only playing a
supporting role (see Table 1). In the traditional model,
physicians were responsible for all tasks. Equally, at pri-
mary health centers, the bulk of medical care was pro-
vided by the visiting physician, who was based in the
district hospital. When relating to HIV care for children,
this reliance on physicians/hospital-based care was even
more pronounced as it was believed to be more difficult
care.
In the Rwandan health system, nurses are classified into
three levels according to their level of training: 1) A3
nurses may have no/minimal secondary training and min-
imal health training; 2) A2 nurses (the bulk of the health
workforce) have two years of secondary education and
two years of nursing training; 3) A1 nurses have received
two additional years of nursing training after finishing
secondary school [22]. Whereas initially A1 nurses were
rarely found at health centers, this is gradually changing.
Currently, no other non-physician clinician cadres are
being trained.
Study sites
The two clinics in this report were Kimironko and Kiny-
inya health centers, located in Kigali. Kimironko was an
urban government health center with a catchment area of
about 75,000 people while Kinyinya was semi-rural,
being located at the outskirts of Kigali, with an estimated
population of 17,000.
In addition to routine health care, the health centers pro-
vided comprehensive HIV care and started offering ARVs
at a decentralized level, beginning in October 2003 in
Kimironko and followed in January 2004 in Kinyinya.Page 2 of 13
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ART. By July 2007, 3252 patients had been started on ART
within these two clinics and of these, 332 children were
enrolled in the ART program. These two clinics have been
supported by MSF since 2002.
Study population
The analysis included all children enrolled in the HIV pro-
gram who qualified for ARVs from the launch of the ART
program from October 2003 till Jan 1/2007. With data
collected until June 30/2007, all children had been on
ART for at least six months. See Figure 1 for details about
how children were selected for ARVs and their treatment
paths.
Description of the Pediatric HIV program
National government's commitment and external support
The pediatric program in the two clinics was part of the
Rwandan national ART program, essentially run by gov-
ernment health care staff. The national program has seen
a successful scaling-up over the last years, organized
through the National AIDS Control Commission (NACC)
and TRAC. A constructive collaboration with various
international partners has taken place, with substantial
financial support provided by the Global Fund to fight
AIDS, Tuberculosis and Malaria. The government's com-
mitment was demonstrated by providing additional nurs-
ing and laboratory staff as well as ongoing laboratory
services, training and ARV procurement. MSF's contribu-
tions were essentially aimed at increasing the clinics
capacity for ARV care and included training and supervis-
ing staff, refurbishing clinic buildings, upgrading the labs
and providing financial incentives.
Nurse-based treatment and care
Increase and retention of nursing staff
At the launch of the HIV program in 2002, the health cent-
ers were poorly staffed. The increased staffing by the Min-
istry of Health was a critical factor. Whereas the health
center's staff included 7 trained nurses before the launch
of the HIV program in 2002, this had gradually increased
to 28 by the end of 2004 (mainly A2 nurses), when scal-
ing-up began. Overall, around 50% of the entire staff's
time was dedicated to HIV care. To compensate for the
substantial increase in work-load associated with the fast
scaling-up of the ART program, a performance-based
financing mechanism was put in place, initially backed by
MSF.
To avoid overloading the nurses, most of the tasks tradi-
tionally performed by nurses were taken over by new or
reinforced cadres in the health centers: receptionists for
administrative work and data collection/monitoring;
counsellors and community support groups for counsel-
ling; and lab-staff for blood collection.
Table 1: Traditional and modified tasks for nurses and physicians within the HIV/ART care program
MD-CENTERED NURSE-CENTERED
Role MD Role Nurse Role MD Role Nurse
Pre-ART care
Initial physical exam/staging X X
Ordering CD4 count X X X
Assessment of ART eligibility X X
FU of non-eligible patients X X
CTX refill X -b
Complex medical cases X X
ART care
Ordering lab tests X X X
Interpretation of lab tests X X
ART initiation and FU
Non-complex cases X X
Complex casesa X X
ART refill X -b
Register keeping/reporting X -b
Filing of results/medical records X -b
Training/mentoring X
Supervision X
a Complex cases included those with advanced HIV disease, severe/persistent opportunistic infections, severe ART side-effects, suspicion of ART 
failure, severe or recurrent non-adherence to ART.
b Activities taken over from the ARV nurse by other staff.
ART: antiretroviral therapy; FU: follow-up; CTX: cotrimoxazole; MD: medical doctorPage 3 of 13
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When the ART program was launched, each health center
was supported by a HIV physician. Given the high
number of patients in (urgent) need of ART, one of their
main duties was to build local capacity, facilitating a rapid
scaling-up of HIV treatment and care within the health
facilities. From the onset, nursing staff received theoretical
and bed-side training in comprehensive HIV care in gen-
eral, and in pediatric aspects in particular, from the HIV
physician, gradually increasing their knowledge and con-
fidence. Using this knowledge, they were able to initiate
and change ARV treatment (for toxicity or contra-indica-
tions), with medical confirmation, and perform routine
follow-up of the children, aided by simplified treatment
protocols and growth curve charts provided in the consul-
tation rooms. Protocols for recognizing side-effects of
ARVs were standardized and indications for referral to the
physician were defined. Ongoing training and supervision
was ensured by having one full-time equivalent physician
per health center, who was ultimately responsible for the
medical care. As the program matured, physician involve-
ment decreased to a presence two to three times a week. A
great deal of emphasis was placed on comprehensive care
with a family-centered approach including methods to
address the psychosocial issues of HIV. ARVs were dis-
pensed by a nurse with extensive practical experience in
ARVs and additional training through the national pro-
gram.
Mentoring and supervision
Besides consulting the complex/referred cases, the physi-
cian played a major role in assuring the quality of care
provided in the program (Table 1). The physician did not
have a separate consultation office, but reviewed patients
together with the nurses, allowing for ongoing training
and skills-building. In addition, this permitted ongoing
evaluation of the quality of care provided by the nurses,
and to identify areas where additional training was
needed. At the same time, a sample of patient files was
reviewed to assess completeness of care and to trace med-
ical problems. Only if the physician was confident in their
knowledge and skills, were nurses allowed to consult in
the ART program, but they still continued to receive ongo-
ing training and supervision.
Flow diagram of the pediatric HIV programigure 1
Flow diagram of the pediatric HIV program. ART: antiretroviral treatment; PMTCT: Prevention of Mother To Child 
Transmission; WHO: World Health Organization.
HIV/ARV CARE FLOW 
Recruitment 
?? Children of HIV+ adult patients (~90 %) 
?? Orphans (~10 %) 
?? PMTCT and in/out patient services (< 1%)   
?? Transfer from other ART programs (< 1%) 
Pre-test counselling 
?? Group session - caregivers only 
?? Group session caregivers + children 
Post-test counselling 
?? Individual - caregivers 
?? Individual - caregivers + children 
First Assessment Consultation (n=672) 
?? Check caregiver/child treatment literacy 
?? Clinical staging 
?? CD4 count measurement 
?? Cotrimoxazole (CTX) prophylaxis started 
?? Treatment of opportunistic infections  
?? Family testing 
?? Evaluation of psychosocial situation 
 
 
 
 
 
 
WHO criteria for ART 
                                        +                                                   - 
 
                                                                                                    
Pre-ART Consultation (n=315)              Follow-up Consultation (q 1-3 mo) (n=357) 
?? Medical assessment                                Family-testing 
?? Exclusion of tuberculosis         Clinical assessment 
?? Baseline blood tests          CD4 follow-up 
?? Counselling/psychosocial assessment:             CTX adherence and tolerance        
                two sessions with caregiver/child and        Counselling/literacy 
               one at home (if indicated)         Referral for ART if criteria met 
 
Start ART 
 
Follow-up consultation (q 1-2 mo):  
Children's and caregivers attend medical consultation and suppor t groups on the same day. 
?? Clinical assessment 
?? Growth evaluation 
?? Follow-up family testing 
?? Psychosocial assessment: school, nutrition, stigma 
?? ART-tolerance, adherence  
?? Follow-up of CD4 count and viral load Page 4 of 13
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barriers among caregivers
Early in the program, we observed that barriers existed
among the caregivers towards testing their children. Car-
egivers themselves were distressed by their own recent
HIV diagnosis. They were reluctant to discuss testing of
their children, since they felt guilty, fearing the reaction of
the child to their own and the child's disclosure, and
being worried about the health and future of the child
[23-25]. Thus, from the start of the program, support and
discussion groups were organized for the caregivers,
designed to increase their acceptance of their HIV-positive
status, a prerequisite for discussing testing of their chil-
dren. In addition, prior to starting ARVs, individual in-
depth counseling sessions were held with the caregivers to
discuss testing of children in detail [23,25]. Subsequently,
the health center-based support groups were transformed
into community-based support groups. Within these, the
group leaders, serving as role-models of positive living
with HIV, helped to make HIV more easily discussed
within the community and to raise issues like testing of
partners and children.
Timely and careful disclosure and ongoing psychosocial support
In our experience, children were generally not well pre-
pared when they came for testing. Few children knew
exactly why they were there, had little knowledge of HIV
and rarely knew about the status of the caregiver [25,26].
However, the children preferred to be informed about
their and their caretaker's status from the caretaker and
felt cheated when they were not told the truth. Conse-
quently, we tried to involve the caretaker as much as pos-
sible during disclosure. Caretakers were first counseled on
why it was important to talk openly with their children
about HIV, why their active participation was important
for the child, how the child might react, and how they
should respond to questions. During disclosure, we tried
to have the caregiver explain their and the child's status,
while being supported by the counselor [26,27]. The use
of a booklet explaining HIV provided a common language
around HIV (Figure 2).
Testing of children was done on a dedicated day, ensuring
that enough time was available for every child, making the
environment/event more child-friendly and facilitating
on-site training of health care staff in counseling of chil-
dren. Disclosure was considered when the child was > 6
years old [27,28].
Within the child support groups, an environment was cre-
ated by the counselors where the children could express
themselves, raise their questions and worries and develop
a positive attitude towards life with HIV. Most of the
issues discussed were raised by the children themselves
and reflected their deeper feelings: HIV (what, why and
how?), life and death, sexuality, manipulation in the car-
egiver-child relationship and discrimination. The issues
were addressed in several ways using open discussions,
games, fairy-tales and drawings [27,28]. These groups
(consisting of 12–15 children) were organized according
to age and were open to all children from the age of 7
years on, irrespective of taking ARVs. Our approach was
based on general recommendations available within MSF
[27] that were adapted to the local context and taken into
account the capacity/possibilities within the program.
Initially, children were followed medically together with
the adult patients, but had their support groups on sepa-
rate days. Subsequently, a special consultation for chil-
dren, integrating both medical and psychosocial aspects,
was introduced once a week, reducing the amount of
traveling and out-of-school time for the children. It also
allowed them to receive care and follow-up in the pres-
ence of other children, making the whole experience more
child-friendly [27].
Who were the caregivers ?
Close to 65 % of the children were taken care of by one or
both parent(s). Twenty-five percent received care from the
extended family (grand-parents, brothers/sisters, cous-
ins,...), and about 10 % of children were orphans with
Picture from the booklet used to explain HIV/AIDS to chil-drenFig  2
Picture from the booklet used to explain HIV/AIDS 
to children. The booklet is used by caregivers and health 
center staff. This picture is used to explain "what actually is 
blood ?" to the child.
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out the caretaker being tested.
ART eligibility, regimens and safety
Children were started on ART according to the national
guidelines, based on the World Health Organization
(WHO) immunological and clinical eligibility criteria and
using WHO-recommended first line regimens [29]. To
simplify treatment regimens and limit calculation errors,
four weight categories were used to choose the appropri-
ate dosing of the ARVs, as has been described elsewhere
[9,30]. Generic, scored fixed-dose combinations (FDC)
were prescribed as much as possible (Triviro 30/40, Ran-
baxy), containing stavudine/lamivudine/nevirapine. No
quarter-tablets were used (as use of these had not been
validated), only whole or half tablets were prescribed.
When scored FDCs were not available, children were
given either separate medications or were switched to a
zidovudine-containing FDC (Duovir-N, Cipla). Initially,
small children needing syrup formulation were referred to
the central referral hospital in Kigali (CHUK) but from
mid-2005, the syrup was available at the health center
level.
For most children (orphans in particular), a home-visit
was done before ARV initiation to assess the socio-eco-
nomic situation of the family and to provide support
where necessary. Adherence to treatment was evaluated by
self-report using calendars, regular clinical attendance
(monthly pharmacy refills/visits after start-up period) and
pill counts. As well, viral load counts were performed rou-
tinely after the first year of treatment from 2005 [31]. HIV
care, including ARVs, consultations, lab tests and OI med-
ications, were provided free of charge. Transport costs for
the children were covered for families in need.
Side effects were evaluated at each follow-up visit, and
treatment changes were made for grade 3 and 4 events
[29]. Liver function tests were performed at baseline, 2, 4,
8 weeks and then every 6 months and on clinical grounds.
A full blood count was done at baseline, 12 weeks and
then every 6 months and on clinical grounds. For children
on zidovudine, an additional control was done at 4 and 8
weeks.
At the outset, absolute CD4 counts and percentages,
checked every 6 months, were measured with the FACS-
Calibur™ Flow Cytometry System (Becton-Dickenson) at
the National Reference Laboratory (NRL). From 2003–
2004, the FACSCount apparatus (Becton-Dickenson) was
used and percentage counts were calculated based on total
lymphocyte counts of a separate sample.
CD4 percentage counts at baseline were missing for sev-
eral reasons (n = 33). First, due to limitations in the
number of samples that could be handled at the NRL in
the initial stages of the program, some children had no
baseline CD4 counts because they met clinical criteria for
starting ART. Second, for some children transferred from
other sites, the information was unavailable. Finally, if the
total lymphocyte count was not known, the CD4 percent-
age could not be calculated, and absolute CD4 counts
were used for consideration of ART. The median time
from baseline CD4 sample collection to initiation of ARVs
was 53 days (interquartile range 30–79). Viral loads were
analyzed at the NLR by the Ultrasensitive Amplicor assay,
version 1.5 (Roche). All other biochemical tests were per-
formed at Kinyinya health center.
Data collection and statistical analysis
Data were routinely collected during the consultations
using Access® software. Treatment and safety outcomes of
the cohort were analyzed by Stata software 9.0® (STATA
Corp., College Station, Texas, USA). Kaplan-Meier sur-
vival methods were used to estimate the probability of
remaining in care (failure defined as death or lost to fol-
low-up). CD4 percentages were used for children under 5
years to evaluate immunological status and both CD4
counts and absolute counts used for children above 5
years. Weight-for age Z-scores (WAZ) were calculated with
Epi-Info (version 4.3.1; Centers for Disease Control and
Prevention). Data for this study were collected from Octo-
ber 1/2003 until June 30/2007.
Ethics
This study analyzed routinely collected data from the
pediatric HIV program. Approval for publication of this
data and report was received from the NACC and TRAC.
Confidentiality was maintained with no patient identifi-
ers being used. The Ethics Review Board of MSF and the
Rwandan National Ethics Committee gave exemption
from formal ethical review. No informed consent was
obtained for this study.
Results
Characteristics of the study population
Over a period of about 3 years, 315 children were started
on ARVs, with a median age of 7.2 years. Table 2 describes
their characteristics. Approximately 25% were less than 5
years of age, 7 were started before the age of 18 months.
Sixty percent were in WHO stages I and II at treatment ini-
tiation. Fifteen tuberculosis (TB) cases were recorded of
which 4 had extra-pulmonary manifestations. Baseline
CD4 counts percentages were available for 282 children
with a median value of 14%. The median WAZ-score was
– 1.9. The vast majority of children, 89%, started on sta-
vudine/lamivudine/nevirapine, with adult FDC tablets
used for 282 children. The remaining 33 commenced
syrup formulation of whom, by the time of analysis, all
but five had changed to tablets. The median time on ARTPage 6 of 13
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more than one year with a total of 589 patient years of fol-
low-up.
Clinical, immunological and virological outcomes
By June 2007, 84% (265) were still alive and being fol-
lowed-up in the clinics. Thirty (9.5%) had been trans-
ferred to another health facility offering ART. Eight (2.6%)
had died, only 12 (3.8%) were lost to follow-up (defined
as not coming to their last scheduled visit for more than 2
months). Of the 8 deaths, 2 were clearly not linked to
HIV. Kaplan-Meier estimates (Figure 3) showed a proba-
bility of remaining in care of 94.7% and 92.9% at 12 and
24 months respectively (with failure defined as death or
lost-to follow-up). CD4 results, hemoglobin and WAZ all
showed progressive improvement over the treatment
interval (Table 3). Most viral load results were obtained
between and 15 and 23 months and were available for
87% by 18 months on treatment (n = 174). Viral load was
less than < 400 copies/ml in 82.8% of children and
showed satisfactory viral suppression in 86.8%. For 13
children among whom viral loads were detectable, a sec-
ond sample was made available after adherence coun-
seling. The median time from first viral load collection to
the repeat sample was 5.8 months (interquartile range
2.7–8.8). Four out of the 13 positive viral loads became
undetectable and 1 decreased significantly. Two children
were switched to second line treatment. For the remain-
der, adherence problems were still being addressed or cri-
teria to switch were not met.
We only had complete data on pharmacy refill as an indi-
rect measure of adherence to therapy. Allowing a delay of
up to two days (accounting for the security stock), we
defined excellent, good and poor adherence as being
punctual for > 95%, 80–95% or < 80% of the visits respec-
tively. Poor adherence was observed for 5% of the chil-
dren, with the majority having excellent (49%) or good
(46%) adherence.
Safety and tolerance
Among all children placed on ART, a change in therapeu-
tic regimen was required for 46 children (14.6%), out of
whom only 26 (8.3%) were due to toxicity. The start of TB
treatment provoked 18 switches. Toxicity was mainly
related to nevirapine, requiring a treatment change to efa-
virenz (n = 24). Sixteen cases were due to grade 3–4 skin
manifestations of which two were Stevens-Johnson syn-
dromes occurring within 1 month of therapy. Both recov-
ered. Five early changes (within 3 months) were made for
severe hepatitis, with 4 children showing clinical signs,
and 1 child having asymptomatic grade 3 liver toxicity. An
additional three children were changed late (median 9
months) due to symptomatic hepatitis. We observed an
additional 14 children with grade 2 (n = 11) or grade 3 (n
= 3) liver toxicities, mostly occurring within the first
months of ART. In general, these were transient and well
tolerated and did not require treatment change.
Stavudine was changed for one child with severe neurop-
athy, and two cases of lipoatrophy were reported (one
requiring treatment change). No lactic acidosis or anemia
requiring treatment change were observed. Thirteen chil-
dren were found with a hemoglobin level < 7 mg/dl of
which 5 were present at baseline and generally improved
on stavudine-containing ART. Of the others, none were
related to zidovudine and were transient and/or related to
intercurrent infections.
Discussion
This report offers reassuring evidence that health center/
nurse-based ART delivery for children is both feasible and
very effective. The morbidity and mortality results are
comparable to or better than those of other reported stud-
ies, which are essentially hospital-based [5-16]. One of
the strengths of the study is that the therapeutic responses
were confirmed with virological evidence in the majority
Table 2: Characteristics of children started on antiretroviral 
treatment (n = 315)
Age at starta 7.2 (4.5 – 10.4)
< 3 yearsb 38 (12%)
3 – 4.9 yearsb 51 (16%)
5 – 14.9 yearsb 226 (72%)
Sex (male/female)b 157/158 (50/50%)
Clinical WHO-stageqb
WHO stage I 43 (13.7%)
WHO stage II 145 (46.0%)
WHO stage III 115 (36.5%)
WHO stage IV 12 (3.8%)
Weight for age (Z-score) (n = 293)a -1.9 (-3.0;-0.9)
Baseline CD4 count % (n = 282)a 14 (9–18)
< 15%b 158 (56.0%)
15–25%b 118 (41.8%)
> 25%b 6 (2.1%)
Baseline absolute CD4 counts (n= 302)a 345 (229–572)
Baseline hemoglobin (mg/dl)(n = 268)a 11.0 (10.3–11.8)
ART regimenb
d4T/3TC/NVP 281 (89.2%)
d4T/3TC/EFV 6 (1.9%)
AZT/3TC/NVP 19 (6.0%)
AZT/3TC/EFV 9 (2.9%)
Time on ART (years)c 2.0 (1.2–2.6)
Total patient years of follow-up 598
On tablets (FDC) 577
On syrup 21
< 1 year vs. ≥ 1 yearb 59 (19 %) vs 256 (81 %)
a Values are expressed as median (interquartile range)
b Values are expressed as n (%)
c As of June 30/2007 (closing date of dataset)
WHO: world health organization; ART: antiretroviral treatment; d4T: 
stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; AZT: 
zidovudine; FDC: fixed-dose combinationPage 7 of 13
(page number not for citation purposes)
BMC Pediatrics 2008, 8:39 http://www.biomedcentral.com/1471-2431/8/39of children. This is very important since it suggests that
clinic-based programs can provide high quality care with-
out over-reliance on the most sparse human resources in
the health system and is thus more likely adapted to and
sustainable within this context. In addition, decentral-
ized/nurse-based care might have potential advantages
over hospital/physician-centered care in providing acces-
sible and comprehensive HIV care to children.
Reinforcing nurse-based care
The shortage of physicians in many African countries
requires a more strategic use of their skills, without com-
promising quality of care. The health center-based care
described here was provided to a large extent by nurses,
with appropriate physician supervision. A most important
factor in the success of the program was the increase in
number of nurses, a human resource pool relatively more
available in Rwanda and many African countries, in the
health facilities by the Ministry of Health. A substantial
part of the physician's role was to ensure ongoing on-site
training, mentoring and supervision, to gradually increase
the capacity and skills of the nurses. Although considera-
ble energy and time were spent on this, especially early in
the program, in our experience it clearly paid off in the
end. Capitalizing on the potential of the nurses allowed
for a rapid scaling-up that would have been difficult, if not
impossible, to achieve when relying on physicians only
for ART care. At the same time, we would like to caution
against over-reliance on nursing skills for ART care in the
absence of adequate supervision [32]. We believe that the
complementary interplay between nurses' and physicians'
skills has been important to achieve good results.
Another important element of success has been the high
retention of nurses. We think that the main contributing
factors have been the continuous training and skills build-
ing, the high quality of care provided and patients' satis-
faction, the increase in nursing staff to meet the demand,
the promotion of responsibilities for the staff in the
project and the performance-based financial incentives
[4,33,34]. In addition, the creation of new support staff
that took over some nursing duties has avoided overload-
Kaplan Meier curve depicting the probability of survival or retention into the antiretroviral treatment (ART) program (n = 315)Figure 3
Kaplan Meier curve depicting the probability of survival or retention into the antiretroviral treatment (ART) 
program (n = 315). Children that had died or were lost to follow-up were considered as non-retained into ART care.
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pool of nurses skilled in HIV care. Over time, consulting
nurses with 3–5 years experience in ART care have become
more involved in the training of other nurses, and cur-
rently function as a source of reference. Their experience
has also allowed a gradual decrease of physician involve-
ment to a presence two to three times a week.
Decentralized care: increased accessibility and 
acceptability
Centralized HIV care at the hospital level tends to create
additional bottlenecks in treatment initiation, and creates
difficulties with transport and time off work for the
patients [29,35,36]. It has been observed in other settings
that, relative to nurse/health center based ART delivery,
the overall capacity of hospital/physician based ART care
in number of patients that can be treated is far more lim-
ited, which obviously raises concerns about access to and
quality of care provided [34]. The fact that this program
was based at a decentralized level might have contributed
to earlier diagnosis and good adherence in the program in
a number of ways. First, although the distance to the clos-
est hospital was not enormous given the urban setting (1–
2 hours walk), geographical proximity is still likely to
have facilitated increased access and acceptability for both
caregivers and children, and this is consistent with find-
ings from other studies [37]. This will obviously be more
important in rural settings. In addition, we were able to
provide comprehensive and patient-centered care, within
a family-based approach, closely linked with the commu-
nity. Having all staff trained in HIV/ARV care meant that
they were sensitized to the issues in all service areas. Care
and counseling could be provided at every patient
encounter, and were not limited to the physician's consul-
tation or a specific service as is often the case in the hospi-
tal setting. Convenient scheduling of visits also facilitated
accessibility as did comprehensive care that was provided
free of charge [37]. The very low rate of lost to follow-up
observed in our program seems to confirm that services
were 'user friendly'.
Nurse-based care – multiplying care capability
By 2005, physicians constituted 4.2% of the total health
work force in Rwanda, 52.2% were nurses [22]. Recent
estimates from Rwanda suggest that approximately one
full-time equivalent physician would be needed for 500
patients on ART within the traditional ART care model
[19]. A simulation model for ART care delivery in Rwanda
estimated that allowing nurses to initiate and follow the
ART treatment for non-complex cases would see a 76%
reduction in physician demand for HIV care or an 170%
increase in physician capacity for non-HIV care [19].
Within the nurse-centered model, as described here, we
equally observed a gradual decrease in the need of physi-
cian time to approximately one full-time equivalent phy-
sician for 1500 patients after the first capacity had been
built within the health centers and one equivalent for
3000 patients at later stages. Although investment in
human resources at all levels remains a priority, nurse-
centered ART care constitutes a more rational use of the
human resources currently available.
Table 3: Clinical, immunological and virological outcomes for children on antiretroviral treatment (n = 315)
Baseline 6 months 12 months 24 months 36 months
CD4 count
< 5 years (%)a 16 30 32 33 35
IQR (12–19) (23–35) (26–34) (28–36) (28–40)
N 84 59 48 39 7
≥ 5 years (%)a 13 25 26 29 29
IQR (9–17) (18–29) (21–32) (24–34) (19–33)
N 198 175 117 80 24
≥ 5 years (abs)a 297 550 624 704 616
IQR (181–405) (337–747) (459–840) (562–866) (492–865)
N 217 183 120 80 24
Hb (mg/dl)b 11.0 12.1 12.6 12.9 13.7
WAZa -1.9 -1.6 -1.6 -1.5 -1.5
IQR (-3.0;-0.9) (-2.6;-0.8) (-2.6;-0.7) (-2.5;-0.6) (-2.7;-0.6)
Viral load Months on ARTa < 40 c/mlc < 400 c/mlc < 5000 c/mlc
(n = 174) 18 (15–23) 127 (73.0%) 144 (82.8%) 151 (86.8%)
a Values are expressed as median (interquartile Range (IQR));
b Values are expressed as median;
c Values are expressed as n (%)
abs: absolute CD4 count (in cells/μL); Hb: hemoglobine; WAZ: Weight-for-age Z-score; ART: antiretroviral treatmentPage 9 of 13
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We started ART in a relatively healthy cohort of children,
as seen from the clinical and immunological baseline
data. This, in turn, was due mostly to our identifying chil-
dren earlier in their disease. From the outset, a family-cen-
tered approach was implemented with a strong focus on
the psychosocial aspects of HIV care (Table 4). This played
a crucial role in overcoming barriers to routine testing of
children. Dealing with the HIV-infected adults' psychoso-
cial issues allowed the staff to introduce the idea of testing
children, and helped them prepare the children for disclo-
sure [25,38]. Although it remains hypothetical, we think
that this sensitive approach, combined with the goal of
routinely testing all children of adult HIV-infected
patients, facilitated the early diagnoses reflected here. Our
experience also demonstrated that there was a significant
burden of HIV illness in children that was readily identifi-
able through HIV-infected adult caregivers. Over 90% of
the children in this cohort came from this source.
In addition, once children tested positive, the psychoso-
cial emphasis provided effective means for handling dis-
closure and subsequent commencement of ARV
treatment. Preparation of both caregivers and children
contributed to good adherence and treatment outcomes
[24,39]. This supports previous research that emphasizes
that HIV care is more than getting CD4 counts and pre-
scribing ARVs. Addressing the many psychosocial aspects
of the illness is crucial to effective treatment programs
[23,38,40]. Whereas this has been effectively imple-
mented in high-income countries and in some hospital-
based settings in low-income countries, we think this
aspect of pediatric ART has not received sufficient atten-
tion in decentralized contexts [17]. Our program experi-
ence emphasizes the need and feasibility of providing
psychosocial support within health center-based pediatric
ART programs.
Safety
In our program, ART was safe and very well tolerated, with
few severe side-effects reported. In concordance with oth-
ers [5,12], tolerance of ART seemed to be as good or better
in children than in adults, arguing against the need for
specialist care for pediatric ART and in favor of providing
ART treatment to children at a decentralized level. In addi-
tion, treating a healthier population was also likely to
reduce side-effects.
Virtually all treatment changes for side-effects or contra-
indications were initiated by the nurses, and confirmed by
the physicians, in patients with clinically recognizable
symptoms. This is reassuring for decentralized pediatric
treatment in rural areas where laboratory monitoring
might not be available. Few children had to change ther-
apy due to rashes or hepatitis. No adverse effects resulted
in death. No cases of severe anemia or lactic acidosis
reported, while neuropathy and lipoatrophy were
extremely rare. One could argue that the low rate of side-
effects could be explained by their having been missed by
the nurses. However, within this program, side-effects
were documented and treated by the same nurses who
managed our adult cohort [41,42], at a frequency similar
to other studies [35,43-45]. Although diagnosing ART tox-
icity in children might be more challenging, children were
additionally monitored through chart review and virtually
all were seen by a physician at some point in time. Side-
effects missed by the nurses were extremely rare.
Replication/sustainability
We are confident that this kind of program could be rep-
licated in other settings and is sustainable. The program
was run in health centers that were already providing a full
range of primary care services. The success of the program
depended, to a large extent, on the commitment of the
government. The increased staffing was a critical factor.
Table 4: Psychosocial aspects of the pediatric HIV program
Caregiver-centered approaches
- organization of discussion/support groups, at health center and in community
- family-based approach to identify eligible children
- individual counseling (pre-ART)
- psychosocial issues addressed in follow-up care
Child-centered approaches
- adapted counseling for children for disclosure and ART (child-adapted tool)
- designated days for children's clinics
- child support groups
- integrated care, including disclosure, with their caregivers
Health-staff centered approaches
- discussion groups for health care staff
- training on psychosocial implications of HIV
- practical training by psychosocial team (check-lists,...)
- supervision and mentoring
ART: antiretroviral treatment
HIV: human immunodeficiency virusPage 10 of 13
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at capacity building (training, infrastructure, logistics)
and has gradually been taken over through the maturing
national ART program. The financial incentives provided
by MSF were subsequently replaced by a performance-
based pay initiative of the Ministry of Health, gradually
implemented since 2005 [46]. In addition, all nurses in
the public sector have seen a substantial increase in salary.
The supervising and mentoring role of the health center-
based physician has been gradually taken over by the vis-
iting district physician. This transition has been aided by
additional training and quality assurance provided by the
national ART program and performance-based financing.
The external support decreased gradually over the years,
and MSF handed over the project to the Ministry at the
end of 2007. Although a follow-up visit by mid 2008
could not reveal any major problems subsequent to the
hand-over, this should ideally be reassessed in a few years
time.
Another program in Rwanda recently reported excellent
patient outcomes for their adult population and good
compliance with national guidelines using a health
center/nurse-based model [47]. The national program is
currently considering expanding this model of care at the
national level.
It is important to note that this program, especially the
psychosocial elements, was developed over several years
and in response to perceived needs of the children and
caregivers. This helps explain the ongoing changes we
describe, reflecting the subsequent barriers we encoun-
tered regarding testing and treatment of children. It is not
necessary that the full structure described here be opera-
tional at the outset of a program, but could be developed
over time, depending on facilities and staffing availability
and on the evolving challenges.
Remaining challenges
While the program successfully managed to build nursing
skills and to redefine the role of the physician, high qual-
ity of care will require further training for nurses and
redefinition of the tasks and responsibilities of the nurses
and physicians, based on the evolving challenges. Treat-
ment failure, an inevitable clinical challenge for the
future, in particular, will require a careful mix of physi-
cians' and nurses' skills. In addition, increasing problems
of acceptance and adherence can be expected in the long
run, especially during adolescence. To what extent these
will be successfully managed within the program remains
to be seen.
Given the severe lack of human resources for health care
at all the levels in most low-income countries and the pro-
nounced increase in need to achieve universal access to
HIV care, task shifting can only be successful in the long-
term when combined with investment in human
resources at all levels [32].
Limitations
Given our relatively healthy cohort, we are cautious in
suggesting that similar outcomes would be possible with
a sicker population. Since CD4 counts were not available
for all children, and some children were started on clinical
grounds, the missing baseline CD4 counts might have
biased the baseline values to some extent. Consequently,
it is possible that the comparison between baseline and
follow-up CD4 counts is not entirely accurate, but we
believe the differences would be minor. Similarly, we only
recorded 87% of viral loads by 18 months. Given the sim-
ilar baseline characteristics, we have no reason to believe
that the results of patients with missing values would be
substantially different. We also note that this cohort
included few young children and we cannot be sure if sim-
ilar outcomes would apply to them. At the early stages of
the program, the youngest children depended on the uni-
versity hospital to receive their ARVs in syrup formulation
before it become available at the health center level. Since
this only involved 9 children, we do not think this could
significantly affect the program outcomes. The health
centers received targeted support from MSF that has been
gradually withdrawn. Although the program seems to be
sustainable, with quality of care remaining high, its future
success will depend on the governments' ongoing com-
mitment and resources.
To what extent local factors influenced the outcomes of
the program remains to be determined. This program was
part of and has benefited from the successful scaling-up of
the Rwandan National HIV program. The HIV prevalence
rate in Rwanda is lower than most Sub-Saharan African
countries. The context of HIV has certain particularities
linked to the history of genocide.
Finally, although the program appeared to have been suc-
cessful, at least in treatment outcome terms, caregivers'
and children's perceptions and satisfaction were not
known and should be assessed. This information could
potentially be an important determinant of long-term suc-
cess of pediatric ART programs, where the psychosocial
consequences of HIV and the overall impact on childrens'
lives might be even more pronounced than for adults
[17].
Future research
This study points to further research to see whether this
health center model could be successful with sicker and/
or younger populations. Whether this approach of decen-
tralized nurse-based pediatric ART programs can be repli-
cated in other contexts remains to be established.Page 11 of 13
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social aspects of care were received would be useful to
refine this part of the program.
Conclusion
Our program shows that, given a strong psychosocial
emphasis, health center/nurse-based ART delivery for chil-
dren is both feasible and very effective, and can at the
same time avoid barriers to care related to the scarcity of
physicians. Providing comprehensive care close to the
community can play an important role in achieving uni-
versal access to HIV care for all children.
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